Results 71 to 80 of about 75,048 (254)

Glucagon-Like Peptide-1 and Diabetes 2012

Experimental Diabetes Research, 2012
The present special issue was aimed at elucidating the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. GLP-1 is a gastrointestinal hormone, mainly secreted after meals, capable of increasing glucose-stimulated insulin release and inhibits food intake.
MONAMI, MATTEO, Di Pasquale G, Rowzee A, ROTELLA, CARLO MARIA, MANNUCCI, EDOARDO   +4 more
openaire   +3 more sources

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Study the Levels of Glucagon Like Peptide-1(GLP-1) and Related Parameters in Iraqi Hyperlipidemia Patients with Diabetes Mellitus.

Ibn Al-Haitham Journal for Pure and Applied Sciences, 2017
     The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels , additionally ...
Ahmed A. Lazim, Muntaha A. Lafta
doaj  

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Journal of Pharmaceutical Policy and Practice
Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano, Mouna Dardouri, Gina D. Moore, Joseph J. Saseen, Kavita V. Nair   +4 more
doaj   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Nele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, Juan José Perez Ruixo, Saberi Rana Ali, Iolanda Cirillo, Oliver Ackaert   +6 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]

Electronic Physician, 2013
:Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri, Sara Heidarzadeh, Parvin Farzanegi, Mohammad Ali Azarbayjani   +3 more
doaj  

Glucagon-like peptide-1 and satiety [PDF]

Nature, 1997
G, van Dijk, T E, Thiele, R J, Seeley, S C, Woods, I L, Bernstein   +4 more
openaire   +2 more sources

Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics

Chemistry – A European Journal, EarlyView.
A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova, Jan L. Venne, Sona Krajcovicova, James Dodgson, Wouter F. J. Hogendorf, Thomas E. Nielsen, David Hymel, Hannah Bolt, Andie Collinson, Jason Day, Jefferson Revell, David R. Spring   +11 more
wiley   +1 more source